If you have any problems related to the accessibility of any content (or if you want to request that a specific publication be accessible), please contact us at email@example.com.
|Author||Kohlenberg, Barbara S.|
|Author||Antonuccio, David O.|
|Author||Hayes, Steven C.|
|Author||Gifford, Elizabeth V.|
|Author||Piasecki, Melissa P.|
|Date of Issue||2004|
|Description||Background: Bupropion SR ( Zyban) has been shown in randomized controlled trials to be an efficacious pharmacological aid for smoking cessation; however, recent reports have raised serious concerns about the breadth of its applicability without complications or contraindications. Methods: We examined this issue in a well-documented medical population, i.e. veterans volunteering to participate in a smoking cessation treatment research program involving the use of bupropion SR. Results: Overall, 22% of the 78 subjects who met the study criteria were appropriate for and completed the course of medication. Conclusions: Thus, bupropion SR in nicotine-dependent veterans may not be broadly applicable when conservative prescribing guidelines are carefully followed. Copyright (C) 2004 S. Karger AG, Basel.|
|Title||Suitability of Bupropion SR for nicotine-dependent smokers: Problems in a practice setting|
Files in this item
There are no files associated with this item.